Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25%
ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented
clinical diagnosis of dry eye disease. The product will be studied over 14 days, with 1-2
drops instilled in each eye four times daily (QID).